AIM: To identify and quantify the prevalence of patients with uveitis receiving systemic immunosuppression in Scotland. METHODS: Anonymised data were prospectively collected on all patients with uveitis requiring systemic immunosuppression. Seven health boards participated over a 4-month period between 1 August 2005 and 30 November 2005. RESULTS: 373 patients were identified, of whom 205 (55%) were female. The mean age was 46.4 (range 7-97 years). Using the data from the seven participating health boards, an estimated Scottish prevalence of 9 per 100 000 was calculated. Prevalence varied between 2 and 59 per 100 000. In National Health Service Grampian, all patients with uveitis, whether sight-threatening or not, are followed up at a specialist clinic. Extrapolating this figure to Scotland gives a prevalence of 25 per 100 000. DISCUSSION: The data from National Health Service Grampian suggest that there is a significant shortfall in the number of patients identified by survey. If the "missing population" exists, then where are they? Some might be receiving appropriate treatment at non-specialist clinics, although simple under-reporting may play a part. Greater concern is for those patients receiving inappropriate treatment for their uveitis, or for those within the community who are either oblivious to or in self denial of their condition.
AIM: To identify and quantify the prevalence of patients with uveitis receiving systemic immunosuppression in Scotland. METHODS: Anonymised data were prospectively collected on all patients with uveitis requiring systemic immunosuppression. Seven health boards participated over a 4-month period between 1 August 2005 and 30 November 2005. RESULTS: 373 patients were identified, of whom 205 (55%) were female. The mean age was 46.4 (range 7-97 years). Using the data from the seven participating health boards, an estimated Scottish prevalence of 9 per 100 000 was calculated. Prevalence varied between 2 and 59 per 100 000. In National Health Service Grampian, all patients with uveitis, whether sight-threatening or not, are followed up at a specialist clinic. Extrapolating this figure to Scotland gives a prevalence of 25 per 100 000. DISCUSSION: The data from National Health Service Grampian suggest that there is a significant shortfall in the number of patients identified by survey. If the "missing population" exists, then where are they? Some might be receiving appropriate treatment at non-specialist clinics, although simple under-reporting may play a part. Greater concern is for those patients receiving inappropriate treatment for their uveitis, or for those within the community who are either oblivious to or in self denial of their condition.
Authors: David A Copland; Jian Liu; Lauren P Schewitz-Bowers; Volker Brinkmann; Karen Anderson; Lindsay B Nicholson; Andrew D Dick Journal: Am J Pathol Date: 2011-11-24 Impact factor: 4.307
Authors: Robert J Barry; Mohammad O Tallouzi; Nick Bucknall; Jonathan M Mathers; Philip I Murray; Melanie J Calvert; David J Moore; Alastair K Denniston Journal: Cochrane Database Syst Rev Date: 2018-12-18
Authors: Alastair K Denniston; Gary N Holland; Andrej Kidess; Robert B Nussenblatt; Annabelle A Okada; James T Rosenbaum; Andrew D Dick Journal: Orphanet J Rare Dis Date: 2015-08-19 Impact factor: 4.123
Authors: Mohammad O Tallouzi; David J Moore; Melanie Calvert; Philip I Murray; Nicholas Bucknall; Alastair K Denniston Journal: Syst Rev Date: 2016-02-13
Authors: Michael M Altaweel; Sapna S Gangaputra; Jennifer E Thorne; James P Dunn; Susan G Elner; Glenn J Jaffe; Rosa Y Kim; P Kumar Rao; Susan B Reed; John H Kempen Journal: J Ophthalmic Inflamm Infect Date: 2016-09-09
Authors: Mohammad O Tallouzi; Jonathan M Mathers; David J Moore; Philip I Murray; Nicholas Bucknall; Jane M Blazeby; Melanie Calvert; Alastair K Denniston Journal: Trials Date: 2017-12-01 Impact factor: 2.279
Authors: Rose M Gilbert; Xiaozhe Zhang; Robert D Sampson; Michael R Ehrenstein; Dao X Nguyen; Mahid Chaudhry; Charles Mein; Nadiya Mahmud; Grazyna Galatowicz; Oren Tomkins-Netzer; Virginia L Calder; Sue Lightman Journal: Front Immunol Date: 2018-05-03 Impact factor: 7.561